A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

NCT ID: NCT06161220

Last Updated: 2024-03-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-30
• Study Completion Date: 2023-12-05

Brief Summary

The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.

Conditions

Cardiac Repolarization in Healthy Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Carbidopa capsule

Dose: 4x 100 mg

Group Type: EXPERIMENTAL

Carbidopa capsule

Intervention Type: DRUG

Dose: 4x 100 mg

Moxifloxacin Tablets, USP

Intervention Type: DRUG

Dose: 400 mg

Placebo

Intervention Type: DRUG

Placebo capsules matching the carbidopa capsules

Moxifloxacin Tablets, USP

Dose: 400 mg

Group Type: ACTIVE_COMPARATOR

Carbidopa capsule

Intervention Type: DRUG

Dose: 4x 100 mg

Moxifloxacin Tablets, USP

Intervention Type: DRUG

Dose: 400 mg

Placebo

Intervention Type: DRUG

Placebo capsules matching the carbidopa capsules

Placebo

Group Type: PLACEBO_COMPARATOR

Carbidopa capsule

Intervention Type: DRUG

Dose: 4x 100 mg

Moxifloxacin Tablets, USP

Intervention Type: DRUG

Dose: 400 mg

Placebo

Intervention Type: DRUG

Placebo capsules matching the carbidopa capsules

Interventions

Carbidopa capsule

Dose: 4x 100 mg

Intervention Type: DRUG

Moxifloxacin Tablets, USP

Dose: 400 mg

Intervention Type: DRUG

Placebo

Placebo capsules matching the carbidopa capsules

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy males and females aged 18 to 55 years (both inclusive)
• For female subjects of childbearing potential, use of double contraception method
• Body Mass Index (BMI) 18.5 to <30 kg/m² at Screening, with a minimum weight of 55kg
• Subject with no clinically significant abnormal serum biochemistry, hematology and urine examination values at screening
• Subject with negative urine screen for drugs of abuse at screening
• Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C) results at screening
• Subject must be willing to communicate with the investigator and site staff and comply with all study procedures and requirements
• Subject must be able to provide written, informed consent including compliance with the requirements listed in the consent form
• Subject must be able and willing to swallow whole capsules without breaking, cutting, or chewing

Exclusion Criteria

• History or presence of systemic diseases at Screening, which as judged by the investigator, may affect the outcome of this study, include, but not limited to significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
• Female subjects who are pregnant or lactating
• Knowledge of any kind of cardiovascular disorder/condition known to increase the possibility of QT prolongation or history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome or Brugada Syndrome) or cardiac conduction disorders
• Resting supine heart rate less than 50 beats per minute or greater than 100 beats per minute
• Resting supine systolic blood pressure less than 90 mmHg or greater than 140 mmHg; resting supine diastolic blood pressure less than 50 mmHg or greater than 90 mmHg.
• Clinically significant (as determined by the Investigator) ECG abnormalities at Screening, including:

1. QTcF > 450 ms for female and >430 ms for male

2. QRS > 110 ms

3. PR > 200 ms

4. QTcF > 450 ms for female and >430 for male

5. QRS > 110 ms

6. PR > 200 ms

7. Resting supine HR <50 beats per minute (bpm) or >100 bpm (may be repeated once at the discretion of the investigator)

8. Second or third-degree AV block

9. Any rhythm other than sinus rhythm, which is interpreted by the Investigator to be clinically significant

10. Bundle Branch Block

11. premature atrial and ventricular contractions,

12. nonspecific T-wave changes

• Positive urine/serum drug screen at Screening or Day -1 for each Period
• History of significant alcohol abuse or drug abuse within one year prior to Screening.
• Use of prescription medication (with the exception of medically approved hormonal contraceptives) including MAO inhibitors in the 30 days prior to admission into Period 1 and over-the-counter medications including vaccines, vitamins, and herbal remedies within 14 days prior to admission of Period 1 till completion of the study (EOS or ET)
• History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations or near drowning with hospital admission
• Subjects who received any investigational drug within the longer of 30 days or 5 half-lives of Day 1 dosing of SM
• Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study
• Use of medications in the 90 days before admission of the study that are known to prolong the QT/QTc interval.
• Family history of QTc prolongation or of unexplainable sudden death at <50 years of age. For this study, family is defined as 1st degree relative (i.e., mother, father, siblings, children) or 2nd degree relative (grandparents, grandchildren, half-siblings, aunt/uncle, niece/nephew).
• Subjects who cannot refrain from using tobacco of any kind within 30 days prior to admission (Day -1) of Period 1 until the last blood sample collection of study
• Subjects who cannot refrain from consumption of alcohol or alcohol containing products or xanthine-containing foods or beverages (like chocolate, tea, coffee or cola drinks) within 48 hours prior to admission (Day -1) of Period 1 till the last blood sample collection of study
• Subjects who participate in other drug research study during the study.
• Subjects who cannot refrain from donating blood or plasma for 30 days and 14 days (respectively) prior to dosing, during the study, and for at least 4 weeks after completing the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Impax Laboratories, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

AXIS Clinicals, LLC

Dilworth, Minnesota, United States

Countries

United States

Other Identifiers

IPX203-102-23

Identifier Type: -

Identifier Source: org_study_id